Hantavirus Diagnostics Challenge West African Labs Amidst MV Hondius Andes Outbreak

Diagnostics Under Scrutiny: PCR vs. Serology for Novel Hantavirus

The ongoing hantavirus event originating from the MV Hondius Andes, anchored off Praia, Cape Verde, continues to put bigly strain on diagnostic capabilities, particularly in West Africa. The identification of a potentially novel hantavirus strain has amplified the challenges inherent in accurately and rapidly diagnosing infected individuals, with specific focus on the differing applications and limitations of RT-PCR and serological testing. Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) remains the gold standard for detecting active viral infections. Its strength lies in identifying the genetic material of the virus, indicating current or recent infection. For the hantavirus event, RT-PCR is crucial during the early stages of illness when viraemia is present. According to scientific guidance issued by the World Health Organization (WHO), samples collected during the acute phase (typically the first few days of symptom onset) are most suitable for RT-PCR, providing a definitive answer to active viral presence. Yet, a key limitation of RT-PCR for hantaviruses, especially those causing Hantavirus Cardiopulmonary Syndrome (HCPS) – a clinical presentation observed in some cases linked to the MV Hondius Andes event. Precise figures are not yet released – is the transient nature of viraemia. In multiple hantavirus infections, viraemia can be short-lived, potentially becoming undetectable by the time severe symptoms manifest. This timing window necessitates rapid sample collection and processing, a logistical hurdle in an unfolding outbreak scenario involving a highly mobile population, such as cruise ship passengers and crew.

Serology's Role: Identifying Past and Present Exposure

Serological testing, which detects antibodies produced by the immune system in response to an infection, complements RT-PCR by identifying both recent and past exposures. IgM antibodies typically appear shortly after symptom onset and can persist for weeks to months, indicating a relatively recent infection. IgG antibodies, on the other hand, develop later but can remain detectable for years, signaling past exposure and immunity. For hantaviruses, serological assays are invaluable for confirming diagnoses in patients presenting later in their illness when RT-PCR may yield negative results due to cleared viraemia. They're also critical for epidemiological studies, helping to understand the true extent of an outbreak by identifying individuals who may have had mild or asymptomatic infections. Yet, serology is not without its challenges. The primary concern with hantavirus serology, particularly with a potentially novel or less common strain, is cross-reactivity. Antibodies developed against one hantavirus species can sometimes react with antigens from other, related hantavirus species, leading to false positives or ambiguous results. This issue is particularly pertinent in regions where multiple hantavirus species might co-circulate, or where diagnostic kits are designed for well-known strains (e.g., European or American hantaviruses) but are being used to detect an emerging variant. The need for strain-specific antigens in diagnostic tests is paramount to ensure accuracy, a process that can take time to develop and validate for a new pathogen.

West African Laboratory Capacity Under Strain

The logistical and technical complexities of hantavirus diagnostics are compounded by the existing laboratory capacity in West Africa. While countries like Cape Verde have made strides in public health infrastructure, the ability to conduct sophisticated molecular and serological testing for emerging and exotic pathogens like hantavirus at scale is often concentrated in national reference laboratories or requires international support. Resources for specialized equipment, trained personnel, and consistent supply chains for reagents can be limited. Rapid diagnostic tests (RDTs) for hantaviruses exist yet often lack the sensitivity and specificity of laboratory-based PCR and ELISA tests, especially for new strains. Their utility for screening needs careful validation against local epidemiology. The reliance on sending samples to international reference centers, such as those coordinated by the WHO or regional bodies like Africa CDC, inevitably introduces delays in diagnosis and public health response. These delays can impact patient management, contact tracing, and broader outbreak control measures. As of late August 2026, international health organizations and national public health agencies in the region are actively collaborating to bolster diagnostic capabilities. This includes deploying mobile laboratory units, providing technical training, and ensuring the supply of appropriate testing kits. The ongoing situation with the MV Hondius Andes hantavirus event underscores the urgent need for sustained investment in strong, adaptable diagnostic infrastructure across West Africa, capable of responding to both known and emergent zoonotic threats. By contrast, the accurate and timely identification of cases remains a cornerstone of effective disease control, especially when dealing with pathogens that present complex diagnostic profiles and regional variability.